Business · Companies · 5 hrs ago
Sanofi avoids EU fine after agreeing to correct rival vaccine claims
The European Commission ended an antitrust probe into Sanofi without fining the company.
The investigation focused on communications aimed mainly at health care professionals in Germany and France.
Regulators said Sanofi may have portrayed Fluad, a flu vaccine made by CSL Seqirus, as inferior to its own Efluelda vaccine.
Fluad was the only rival vaccine recommended for vulnerable patients at risk of developing flu.
Sanofi has agreed to correct its communications and not repeat the conduct.
The commitment is legally binding, and the Commission said it would address possible disparagement.
The agreement matters because Sanofi holds a dominant position in both Germany and France.
The European Commission accepted Sanofi’s commitments to settle an antitrust investigation into claims about a rival flu vaccine.
Sanofi avoided a fine under the agreement, which is legally binding.
The Commission said Sanofi may have portrayed CSL Seqirus’s Fluad vaccine as inferior to its own Efluelda vaccine.
The campaign primarily targeted health care professionals in Germany and France, where the Commission said Sanofi holds a dominant position.
Sanofi committed to run corrective communications and refrain from similar conduct in the future.
- Who
- Sanofi and the European Commission. The investigation concerned CSL Seqirus’s Fluad vaccine.
- What
- The Commission accepted Sanofi’s commitments to settle an antitrust investigation, and Sanofi avoided a fine.
- When
- October 14, 2026.
- Where
- The campaign primarily targeted health care professionals in Germany and France.
- Why
- The Commission investigated whether Sanofi’s campaign disparaged Fluad by portraying it as inferior to Efluelda.
This story does not have two clearly opposing sides.
The European Commission investigated Sanofi’s campaign about CSL Seqirus’s Fluad vaccine.
The Commission accepted Sanofi’s commitments to settle the probe, avoiding a fine.
- Fine
- Sanofi avoided a fine
- Rival vaccine
- Fluad, marketed by CSL Seqirus
- Sanofi vaccine
- Efluelda
- Countries targeted
- Germany and France
- Remedy
- Corrective communications and a commitment to refrain from similar behavior
2 sources
What people are saying
possible disparaging behavior